The issue common to the studies that did not meet the exemption requirements was the inability to provide support for the third criterion on the issue of safety as laid out in 21 CFR 312(b)(iii), which states, ???The investigation does not involve a route of administration or dosage level or use in a patient population or other factor that significantly increases the risks (or decreases the accept